Incyte Corp. (NASDAQ:INCY) traded down 1.6% during trading on Tuesday . The company traded as low as $80.51 and last traded at $80.68, with a volume of 592,682 shares traded. The stock had previously closed at $81.98.

A number of equities research analysts have commented on the stock. Cowen and Company reissued a “buy” rating on shares of Incyte Corp. in a report on Tuesday, May 3rd. Brean Capital reissued a “buy” rating and set a $92.00 price objective on shares of Incyte Corp. in a report on Tuesday, May 10th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Incyte Corp. in a report on Monday, May 2nd. Piper Jaffray Cos. set a $102.00 price objective on shares of Incyte Corp. and gave the stock a “buy” rating in a report on Tuesday, August 16th. Finally, Vetr lowered shares of Incyte Corp. from a “strong-buy” rating to a “buy” rating and set a $76.50 price objective on the stock. in a report on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $105.93.

The stock’s 50 day moving average price is $84.53 and its 200-day moving average price is $77.55. The firm has a market cap of $15.50 billion and a P/E ratio of 224.02.

Incyte Corp. (NASDAQ:INCY) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.20. During the same quarter in the previous year, the company earned $0.05 earnings per share. The company earned $208 million during the quarter, compared to the consensus estimate of $236.91 million. The business’s revenue was up 51.1% on a year-over-year basis. Analysts predict that Incyte Corp. will post $0.18 EPS for the current fiscal year.

In other Incyte Corp. news, EVP Reid M. Huber sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $87.96, for a total transaction of $879,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paula J. Swain sold 60,000 shares of the stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $90.00, for a total value of $5,400,000.00. Following the transaction, the executive vice president now owns 89,248 shares in the company, valued at $8,032,320. The disclosure for this sale can be found here.

Several institutional investors have bought and sold shares of INCY. Calvert Investment Management Inc. boosted its position in Incyte Corp. by 30.1% in the fourth quarter. Calvert Investment Management Inc. now owns 9,550 shares of the biopharmaceutical company’s stock worth $1,036,000 after buying an additional 2,210 shares during the last quarter. Suntrust Banks Inc. boosted its position in Incyte Corp. by 111.1% in the fourth quarter. Suntrust Banks Inc. now owns 13,744 shares of the biopharmaceutical company’s stock worth $1,490,000 after buying an additional 7,232 shares during the last quarter. Finally, KBC Group NV boosted its position in Incyte Corp. by 150.1% in the fourth quarter. KBC Group NV now owns 41,700 shares of the biopharmaceutical company’s stock worth $4,522,000 after buying an additional 25,025 shares during the last quarter.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.